ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo
ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O
ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and more
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Roche’s Tecentriq combo extends life in advanced NSCLC
ASCO 2018 Preview – what to expect from this year’s conference
Merck & Co’s Keytruda could catch BMS’ rival with new lung cancer use